Related Experiment Videos
Long-term amiodarone therapy raises serum cholesterol
A A Lakhdar1, E Farish, W S Hillis
1Department of Medicine, Stobhill General Hospital, Glasgow, UK.
European Journal of Clinical Pharmacology
|January 1, 1991
Summary
Amiodarone treatment significantly increases serum cholesterol levels in patients. Triglycerides and thyroid hormone levels showed no significant changes, indicating potential cardiovascular risks with amiodarone use.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Amiodarone is a widely used antiarrhythmic drug.
- Potential side effects of amiodarone include effects on lipid metabolism and thyroid function.
Purpose of the Study:
- To investigate the effects of amiodarone therapy on serum lipid profiles and thyroid hormone levels.
- To assess the relationship between amiodarone levels and changes in cholesterol and thyroid hormones.
Main Methods:
- Serum total cholesterol, triglycerides, T4, T3, reverse T3, and TSH were measured in 12 patients.
- Measurements were taken before and at 3.6 and 9 months after initiating amiodarone.
- Serum amiodarone and its metabolite levels were also monitored.
Main Results:
- Serum total cholesterol and T4 levels significantly increased from baseline at 6 months.
- Reverse T3 levels increased at 3, 6, and 9 months post-treatment.
- Serum triglycerides and T3 levels did not show significant changes.
- No correlation was found between amiodarone levels and lipid or thyroid hormone changes.
Conclusions:
- Amiodarone therapy is associated with elevated serum cholesterol levels.
- These findings suggest potential clinical implications for cardiovascular risk management in patients on amiodarone.